Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To determine the potential role of intraoperative dexamethasone intravitreal implant (DEX-I) in reducing diabetic macular edema (DME) worsening after phacoemulsification.
Methods: This was a prospective study on 19 eyes of 19 patients with type 2 diabetes mellitus with DME and cataract. Mean preoperative Early Treatment Diabetic Retinopathy Study visual acuity (VA) was 16.7 letters. Mean foveal thickness (FT) was 451 μm. The DME was naive in 11 eyes and refractory in 8 eyes. All eyes underwent a standard phacoemulsification and intraocular lens implantation; DEX-I was injected at the end of surgery. Follow-up was performed at 1 week and then monthly until DME recurrence (up to 8 months).
Results: At 1 week, mean VA improved by 15 letters (range 0-29 letters) and mean FT decreased by 147 μm (range 69-236 μm). Improvement consolidated at month 1, with a mean VA improvement of 18 letters (range 3-32 letters) and a mean improvement in FT of 193 μm (range 76-304 μm), remaining stable at month 2 after surgery in all eyes. The DME recurred in 1 eye at month 3, in 14 eyes (73.8%) between months 4 and 5, and after month 6 in 4 eyes (21%). Refractory DMEs demonstrated the same benefit but recurred earlier than naive ones (4 months versus 5.8 months, p<0.01).
Conclusions: Intraoperative DEX-I prevents DME worsening after phacoemulsification. Its positive effects last for at least 3 months.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5301/ejo.5000920 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Polymer-based gene-drug co-delivery system effectively inhibits pathologic retinal neovascularization through dual anti-inflammatory and anti-neovascular actions.
Biomaterials
September 2025
State Key Laboratory of Physical Chemistry of Solid Surfaces, College of Chemistry and Chemical Engineering, Innovation Laboratory for Sciences and Technologies of Energy Materials of Fujian Province (IKKEM), Xiamen University, Xiamen 361005, China.
Retinal neovascularization is one of the most prevalent fundus neovascular diseases, affecting vision and potentially leading to severe complications, such as retinal detachment or irreversible blindness. Current treatments primarily involve intravitreal injections (IVT) of anti-vascular endothelial growth factor (anti-VEGF) agents. However, such treatment often requires repeated injections, develop incomplete responses, and are associated with adverse effects.
View Article and Find Full Text PDFPars plana vitrectomy with ILM peeling for macular edema of various etiologies: results from the SCRV macula surgery study.
Int Ophthalmol
August 2025
SOS Retine Sud, 29 Boulevard de la Ferrage, 06400, Cannes, France.
Purpose: The aim of this study was to evaluate the outcome and complications associated with pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling in the treatment of macular edema of various etiologies.
Methods: This observational, multicenter, longitudinal, retrospective study, initiated by the Société Française de Chirurgie Rétino-Vitréene in 2022, involved 27 surgeons from all over France. Data were collected preoperatively and at multiple postoperative time periods up to two years.
Are dexamethasone implants a safe and effective breakthrough in uveitis treatment? A systematic review and meta-analysis.
Steroids
August 2025
Department of Ophthalmology, Cardinal Tien Hospital, New Taipei City, Taiwan; School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan. Electronic address:
Background: Uveitis encompasses inflammatory conditions affecting the iris, ciliary body, and choroid. Its management relied on corticosteroids, immunosuppressive agents, and, more recently, biologic therapies. The development of sustained-release intravitreal corticosteroid delivery systems, like dexamethasone intravitreal implants, has revolutionized the treatment of posterior uveitis.
View Article and Find Full Text PDFEfficacy and safety of fluocinolone acetonide intravitreal implant (0.2 µg/day) in patients with post-surgical inflammation associated with macular edema: a case series study.
J Ophthalmic Inflamm Infect
August 2025
Ophthalmology Department, West Lisbon Local Health Unit (Unidade de Saúde Local de Lisboa Ocidental), Rua da Junqueira, 126, Lisbon, 1349-019, Portugal.
Background: Postoperative cystoid macular edema (PCME) is a primary cause of reduced vision following both cataract and/or vitreoretinal surgery, which may spontaneously resolve. This study aimed to evaluate the effectiveness and safety of the fluocinolone acetonide intravitreal (FAc) implant (0.2 µg/day) in patients with refractory PCME.
View Article and Find Full Text PDFGonioscopy-assisted transluminal trabeculotomy for intractable ocular hypertension after repeated intravitreal dexamethasone implant injections.
Int Ophthalmol
August 2025
Department of Ophthalmology, Kırşehir Training and Research Hospital, Ahi Evran University, Kırşehir, Turkey.
Purpose: To evaluate the efficacy and safety of gonioscopy-assisted transluminal trabeculotomy (GATT) in managing intractable ocular hypertension (OHT) following repeated intravitreal dexamethasone implant (DI) injections.
Methods: This retrospective study included patients with steroid-induced OHT unresponsive to maximum tolerated medical therapy who underwent GATT. Primary outcome measures were intraocular pressure (IOP) reduction and surgical success (qualified and complete), number of DI injections.